REPROCELL
Cristina Linde has a diverse work experience, starting as a Biochemist at MEDCENTER from June 2000 to February 2003. Cristina then pursued their education and worked as a Graduate Student at Università degli Studi di Padova from 2004 to 2007. Cristina continued their academic career as a Postdoctoral Fellow at the University of Maryland School of Medicine from May 2007 to February 2013. Following that, they joined Biopta Inc as an Associate Study Director from February 2013 to May 2014. Cristina'smost recent position is with REPROCELL, where they have worked since May 2014, initially as a Study Director and then promoted to Senior Scientist and Study Director in October 2020.
Cristina Linde obtained a PhD in Biochemistry and Biophysics from the Università degli Studi di Padova between 2004 and 2007. Prior to that, they earned a Master of Science (MS) degree in Microbial and Cellular Biotechnologies from the Universitatea "Alexandru Ioan Cuza" din Iași between 1999 and 2001. Cristina also completed a Bachelor's degree in Biochemistry from the same university between 1994 and 1999. There is no information available regarding their education at Costache Negruzzi.
This person is not in any offices
REPROCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES/ iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.